You are here: Industry Insights > Larotrectinib

News List

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors for Vitrakvi americanpharmaceuticalreview
November 02, 2020
The U.S. Food and Drug Administration (FDA) has approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase (NTRK) genes, NTRK1 ...
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund europeanpharmaceuticalreview
April 22, 2020
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) worldpharmanews
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology...
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion worldpharmanews
November 29, 2018
The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®.
US approves first ever TRK inhibitor pharmatimes
November 28, 2018
Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
Loxo Oncology Initiates Rolling Submission of NDA to FDA for Larotrectinib for the Treatment of TRK biospace
December 21, 2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.